Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
GHK-Cu dosage in clinical and research contexts typically ranges from 0.5 to 3 mg administered monthly via subcutaneous injection, though individual protocols vary based on treatment goals and baseline health markers
In contrast, tirzepatide, an active ingredient of Mounjaro and Zepbound, is a dual agonist of the GLP-1 and GIP receptors
This holistic approach will likely improve outcomes and patient satisfaction
Features BPC-157 research compound Synthetic gastric-derived peptide fragment High-purity laboratory-grade material Studied in tissue and cellular research Stable and securely sealed vial Consistent quality for experimental use Intended for research purposes only Applications Tissue repair pathway research Cellular signaling studies Injury response mechanism analysis Gastrointestinal peptide research Laboratory-based biochemical investigations Academic and scientific studies Reviews There are no reviews yet.
US$ 21.94
US$ 28.47
US$ 25.78
